Existential concerns in late stage cancer

2002 ◽  
Vol 6 (4) ◽  
pp. 243-246 ◽  
Author(s):  
C Griffiths ◽  
L Norton ◽  
G Wagstaff ◽  
J Brunas-Wagstaff
Keyword(s):  
Late Stage ◽  
Late Stage Cancer ◽  
Existential Concerns

scholarly journals Insights Into the Reluctance of Patients With Late-Stage Cancer to Adopt Exercise as a Means to Reduce Their Symptoms and Improve Their Function

2012 ◽  
Vol 44 (1) ◽  
pp. 84-94 ◽  
Author(s):  
Andrea L. Cheville ◽  
Ann Marie Dose ◽  
Jeffrey R. Basford ◽  
Lori M. Rhudy
Keyword(s):  
Late Stage ◽  
Late Stage Cancer

Detection of additional occult malignancy though profiling of ctDNA in late-stage cancer patients

2021 ◽  
Author(s):  
M. Aldea ◽  
L. Cerbone ◽  
A. Bayle ◽  
C. Parisi ◽  
C. Sarkozy ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Late Stage ◽  
Late Stage Cancer ◽  
Occult Malignancy

Interpersonal factors predict increased desire for hastened death in late-stage cancer patients

2006 ◽  
Vol 31 (1) ◽  
pp. 63-69 ◽  
Author(s):  
Sean Ransom ◽  
William P. Sacco ◽  
Michael A. Weitzner ◽  
Lora M. Azzarello ◽  
Susan C. McMillan
Keyword(s):  
Cancer Patients ◽  
Late Stage ◽  
Interpersonal Factors ◽  
Late Stage Cancer ◽  
Hastened Death

scholarly journals Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 232 ◽  
Author(s):  
Martin L. Ashdown ◽  
Andrew P. Robinson ◽  
Steven L. Yatomi-Clarke ◽  
M. Luisa Ashdown ◽  
Andrew Allison ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Late Stage ◽  
Meta Analysis ◽  
Complete Response ◽  
Drug Regimen ◽  
Cancer Type ◽  
Late Stage Cancer ◽  
Pubmed Database ◽  
Wide Range ◽  
Cancer Types

Complete response (CR) rates reported for cytotoxic chemotherapy for late-stage cancer patients are generally low, with few exceptions, regardless of the solid cancer type or drug regimen. We investigated CR rates reported in the literature for clinical trials using chemotherapy alone, across a wide range of tumour types and chemotherapeutic regimens, to determine an overall CR rate for late-stage cancers. A total of 141 reports were located using the PubMed database. A meta-analysis was performed of reported CR from 68 chemotherapy trials (total 2732 patients) using standard agents across late-stage solid cancers—a binomial model with random effects was adopted. Mean CR rates were compared for different cancer types, and for chemotherapeutic agents with different mechanisms of action, using a logistic regression. Our results showed that the CR rates for chemotherapy treatment of late-stage cancer were generally low at 7.4%, regardless of the cancer type or drug regimen used. We found no evidence that CR rates differed between different chemotherapy drug types, but amongst different cancer types small CR differences were evident, although none exceeded a mean CR rate of 11%. This remarkable concordance of CR rates regardless of cancer or therapy type remains currently unexplained, and motivates further investigation.

scholarly journals Nutraceutical use in late-stage cancer

2010 ◽  
Vol 29 (3) ◽  
pp. 503-510 ◽  
Author(s):  
Michael J. Wargovich ◽  
Jay Morris ◽  
Vondina Brown ◽  
Jane Ellis ◽  
Britt Logothetis ◽  
...  
Keyword(s):  
Late Stage ◽  
Late Stage Cancer

Estimating Survival for Patients With Late-Stage Cancer

1980 ◽  
Vol 73 (7) ◽  
pp. 838-840 ◽  
Author(s):  
BERNARD S. LINN ◽  
MARGARET W. LINN
Keyword(s):  
Late Stage ◽  
Late Stage Cancer

scholarly journals The effect of Pap smear screening on cervical cancer stage among southern Thai women

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Li Niu ◽  
Shama Virani ◽  
Surichai Bilheem ◽  
Hutcha Sriplung
Keyword(s):  
Cervical Cancer ◽  
Late Stage ◽  
Protective Factor ◽  
Pap Smear ◽  
Early Stage ◽  
Population Based ◽  
Thai Women ◽  
Screening Programs ◽  
Late Stage Cancer ◽  
Pap Smear Screening

AbstractOur study aimed to investigate the effect of Pap smear screening on stage at diagnosis of cervical cancer in a heterogeneous population of Thai women. Data was merged from the population-based cancer registry and screening registry based on unique identification numbers from 2006 to 2014. Patients being screened had lower odds to be diagnosed at late stage. After adjustment, married women had reduced risk of late stage cancer compared to single women. Muslim women had almost twice the risk of being diagnosed late stage compared to Buddhist women. The odds of being diagnosed at late stage decreased with increased number of screening. The probability of being diagnosed at late stage increased rapidly among females aged 40 to 55 years. Pap smear screening is a protective factor in diagnosis of late stage cervical cancer. Patients were more likely to be diagnosed at early stage with more frequent screening. For future screening programs, it will be beneficial to shorten screening intervals and take more concern for vulnerable population: women aged between 40 and 55 years, and women who are single or Muslim.

Sign in / Sign up

Export Citation Format

Share Document